Stock Events

Stock Events

Mersana Therapeutics 

€0.21
50
+€0+0% Friday 19:45

Statistics

Day High
0.22
Day Low
0.21
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-4.87
-3.28
-1.68
-0.09
Expected EPS
-3.054286
Actual EPS
N/A

Financials

-170.53%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
37.82MRevenue
-64.5MNet Income

Analyst Ratings

23.33Average Price Target
The highest estimate is 23.33.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0M4.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap501.13M
ADC Therapeutics develops ADCs targeting hematological malignancies and solid tumors, overlapping with Mersana's focus.
Macrogenics
MGNX
Mkt Cap193.86M
MacroGenics provides innovative antibody-based therapies for cancer, competing in the same biopharmaceutical space as Mersana.
Allogene Therapeutics
ALLO
Mkt Cap794.59M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in cancer treatment.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space with CAR T and other cancer therapies.
Novartis
NVS
Mkt Cap280.79B
Novartis offers a broad range of oncology treatments, including CAR T-cell therapies, competing across multiple areas with Mersana.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has a diverse oncology portfolio, including ADCs, that competes with Mersana's therapeutic approaches.

About

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Martin H. Huber M.D.
Employees
102
Country
Germany
ISIN
US59045L1061
WKN
000A2DTR7

Listings

0 Comments

Share your thoughts

FAQ

What is Mersana Therapeutics stock price today?▼
The current price of 0M4.F is €0.21 EUR — it has increased by +0% in the past 24 hours. Watch Mersana Therapeutics stock price performance more closely on the chart.
What is Mersana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mersana Therapeutics stocks are traded under the ticker 0M4.F.
What is Mersana Therapeutics revenue for the last year?▼
Mersana Therapeutics revenue for the last year amounts to 37.82M EUR.
What is Mersana Therapeutics net income for the last year?▼
0M4.F net income for the last year is -64.5M EUR.
How many employees does Mersana Therapeutics have?▼
As of April 29, 2026, the company has 102 employees.
In which sector is Mersana Therapeutics located?▼
Mersana Therapeutics operates in the Health & Wellness sector.
When did Mersana Therapeutics complete a stock split?▼
Mersana Therapeutics has not had any recent stock splits.
Where is Mersana Therapeutics headquartered?▼
Mersana Therapeutics is headquartered in Cambridge, Germany.